TORS辅助检查后pT0原发灶不明头颈癌的保咽放疗
本研究回顾性分析了TORS辅助检查后pT0原发灶不明头颈癌患者,比较保咽放疗(PSRT)与咽部靶向放疗(PRT)的结局。结果显示PSRT组2年无复发生存率和总生存率与PRT组无显著差异,但PSRT组放疗相关毒性显著降低。
要点
- PSRT组2级及以上黏膜炎、新阿片需求、体重减轻、喂养管置入及非计划住院均显著低于PRT组。
核心结论
- TORS辅助检查后pT0原发灶不明头颈癌患者接受PSRT较PRT毒性显著降低,且未见明显影响肿瘤治愈。
主要发现
- PSRT组和PRT组分别有3例和6例复发。
临床怎么用
- 对于TORS辅助检查后pT0原发灶不明头颈癌患者,可考虑采用保咽放疗以降低治疗毒性,但需进一步验证。
局限性
- 本研究为回顾性研究,证据等级为Level 3,存在选择偏倚等局限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In patients with head and neck carcinoma of unknown primary (HNCUP;pT0) following TORS-assisted workup, we have adopted a pharyngeal-sparing radiation therapy (PSRT) approach targeting only the at-risk neck and omitting treatment of the pharynx. We report outcomes following PSRT, and compare to institutional historical control subjects who received pharyngeal-targeted RT (PRT). METHODS: Between 2009 and 2018, 172 patients underwent TORS-assisted endoscopy as part of their workup for HNCUP. Following TORS, 54 patients had pT0 disease, of which 45 received RT. Forty-nine percent received PSRT and 51% received PRT. RESULTS: No statistically significant differences existed between the PSRT and PRT groups with respect to overall nodal distribution, p16 positivity (55% vs. 43%, P = .12), neck dissection rates (77% vs. 65%, P = .51), and administration of chemotherapy (55% vs. 65%, P = .55). Median follow-up for PSRT and PRT groups were 24 and 28 months, respectively (P = .04). Two-year RFS was 86% and 74% for PSRT and PRT patients, respectively (log-rank P = .30). Three and six patients recurred after PSRT and PRT, respectively. Two-year OS for PSRT and PRT patients was 91% and 74%, respectively (log-rank P = .31). Compared to PRT, PSRT was associated with statistically significantly less: grade 2+ mucositis (18% vs. 91%, P < .01), new opioid requirement (27% vs. 91%, P < .01), mean weight loss during RT (6.2 lbs vs. 17.4 lbs, P < .01), feeding tube placement during RT (5% vs. 43%, P < .01), and treatment-related unplanned hospitalizations (9% vs. 39%, P = .04). CONCLUSION: Following TORS-assisted management of patients with pT0 HNCUP, we observed reduced toxicity following PSRT compared to PRT without apparent compromise of disease cure. LEVEL OF EVIDENCE: Level 3 evidence, retrospective review comparing cases and controls Laryngoscope, 130:691-697, 2020.
引用
- Grewal AS, Rajasekaran K, Cannady SB, et al. Pharyngeal-sparing radiation for head and neck carcinoma of unknown primary following TORS assisted work-up. Laryngoscope. 2019. PMID: 31411747. doi:10.1002/lary.28200
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。